EGFR (Epidermal Growth Factor Receptor) is a receptor tyrosine kinase that is a critical driver of cell proliferation and survival. Its aberrant activation, through overexpression or mutations, is a well-established oncogenic event in multiple cancers, particularly non-small cell lung cancer (NSCLC). This has made EGFR a premier drug target, leading to the development of tyrosine kinase inhibitors (TKIs). A central focus of current EGFR research is understanding and overcoming the inevitable drug resistance that arises to these targeted therapies.